Evaluation of 2,3-dihydroimidazo[2,1-b]oxazole and imidazo[2,1–b]oxazole derivatives as chemotherapeutic agents

Abstract

Imidazo[2,1- b]oxazole and 2,3-dihydroimidazo[2,1- b]oxazole ring systems are commonly employed in therapeutically active molecules. In this article, the authors review the utilization of these core scaffolds as chemotherapeutic agents from 2018 to 2022. These scaffolds possess many important biological activities including antimicrobial and anticancer, among others. This review covers their biological activities and structure–activity relationships. One of the most important drugs in this class of compounds is the antitubercular agent delamanid. In this paper, the compounds structure–activity relationship and preclinical and clinical trial data are thoroughly presented.